APMA News - September/October 2021 - 57

DISCOVER A NEW WORLD
OF POSTOPERATIVE PAIN
MANAGEMENT
With the First and Only Extended-Release Dual-Acting Local Anesthetic (DALA)1-4
ZYNRELEF redefi nes postoperative pain management by providing superior pain relief for up to 72 hours, with fewer patients
experiencing severe pain, and reducing or eliminating the need for opioids in many patients following surgery versus standard-of-care
bupivacaine HCl solution.1-4
SYNERGISTIC
SUPERIOR
MECHANISM OF ACTION1,5,a
72-HOUR PAIN RELIEF1-3,b
OPIOID REDUCTION
& ELIMINATION1-3,b
NEEDLE-FREE
APPLICATION1
aSynergistic increases in analgesia compared with meloxicam or bupivacaine alone shown in preclinical and Phase 2 studies.1,5
b
BROAD ACCESS
PRICING & FAVORABLE
REIMBURSEMENT
Clinical fi ndings were demonstrated in Phase 3 trials for bunionectomy with osteotomy and open inguinal herniorrhaphy comparing ZYNRELEF to both placebo and
bupivacaine HCl solution.1-3
EXPLORE THE DATA AT ZYNRELEF.COM/PODIATRY
Indication
ZYNRELEF is indicated in adults for soft tissue or periarticular
instillation to produce postsurgical analgesia for up to 72 hours
after bunionectomy, open inguinal herniorrhaphy and total knee
arthroplasty.
Limitations of Use: Safety and effi cacy have not been established
in highly vascular surgeries, such as intrathoracic, large multilevel
spinal, and head and neck procedures.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS CARDIOVASCULAR
AND GASTROINTESTINAL EVENTS
* Nonsteroidal anti-infl ammatory drugs (NSAIDs) cause an
increased risk of serious cardiovascular thrombotic events,
including myocardial infarction and stroke, which can be fatal.
This risk may occur early in treatment and may increase with
duration of use.
* ZYNRELEF is contraindicated in the setting of coronary artery
bypass graft (CABG) surgery.
* NSAIDs cause an increased risk of serious gastrointestinal (GI)
adverse events including bleeding, ulceration, and perforation
of the stomach or intestines, which can be fatal. These
events can occur at any time during use and without warning
symptoms. Elderly patients and patients with a prior history of
peptic ulcer disease and/or GI bleeding are at greater risk for
serious GI events.
Contraindications
ZYNRELEF is contraindicated in patients with known
hypersensitivity (eg, anaphylactic reactions and serious skin
reactions) to any amide local anesthetic, NSAIDs, or other
components of ZYNRELEF; with history of asthma, urticaria, or
other allergic-type reactions after taking aspirin or other NSAIDs
(severe, sometimes fatal, anaphylactic reactions to NSAIDS
have been reported in such patients); undergoing obstetrical
paracervical block anesthesia; or undergoing coronary artery
bypass graft (CABG) surgery.
Warnings and Precautions
Dose-Related Toxicity: Monitor cardiovascular and respiratory vital
signs and patient's state of consciousness after application of
ZYNRELEF. When using ZYNRELEF with other local anesthetics,
overall local anesthetic exposure must be considered through
72 hours.
Hepatotoxicity: If abnormal liver tests persist or worsen, perform a
clinical evaluation of the patient.
Hypertension: Patients taking some antihypertensive medication
may have impaired response to these therapies when taking
NSAIDs. Monitor blood pressure.
Heart Failure and Edema: Avoid use of ZYNRELEF in patients with
severe heart failure unless benefi ts are expected to outweigh risk of
worsening heart failure.
Renal Toxicity: Monitor renal function in patients with renal or
hepatic impairment, heart failure, dehydration, or hypovolemia.
Avoid use of ZYNRELEF in patients with advanced renal disease
unless benefi ts are expected to outweigh risk of worsening renal
failure.
Anaphylactic Reactions: Seek emergency help if an anaphylactic
reaction occurs.
© 2021 HERON THERAPEUTICS, INC. ALL RIGHTS RESERVED.
4242 CAMPUS POINT COURT, SUITE 200 * SAN DIEGO, CA 92121 * 858-251-4400
PP-HTX011-0557 | 08/21

http://www.ZYNRELEF.COM/PODIATRY

APMA News - September/October 2021

Table of Contents for the Digital Edition of APMA News - September/October 2021